Previous close | 397.70 |
Open | 393.52 |
Bid | 397.25 x 100 |
Ask | 397.58 x 100 |
Day's range | 393.49 - 399.63 |
52-week range | 320.01 - 448.40 |
Volume | |
Avg. volume | 1,202,646 |
Market cap | 102.732B |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 28.64 |
EPS (TTM) | 13.88 |
Earnings date | 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 465.42 |
LONDON, April 26, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $397.70, moving -0.76% from the previous trading session.